Progenics Pharmaceuticals Inc. (PGNX) Shares Up 2.3%
Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) shot up 2.3% on Wednesday . The stock traded as high as $7.09 and last traded at $7.00, with a volume of 558,962 shares traded. The stock had previously closed at $6.84.
Several research firms have weighed in on PGNX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. Brean Capital reissued a “buy” rating and issued a $14.00 price target on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. Zacks Investment Research downgraded shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 27th. BTIG Research reissued a “buy” rating and issued a $9.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. Finally, Jefferies Group reissued a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $9.95.
The stock’s market cap is $458.40 million. The stock’s 50-day moving average price is $5.97 and its 200-day moving average price is $5.01.
Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.05. During the same period last year, the company earned ($0.17) earnings per share. The firm earned $8.50 million during the quarter, compared to analysts’ expectations of $6.33 million. The business’s revenue for the quarter was up 337.6% on a year-over-year basis. On average, equities analysts expect that Progenics Pharmaceuticals Inc. will post $0.13 EPS for the current fiscal year.
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.